Endpoints News – Biotech and pharma business news, with a focus …
Biotech and pharma business news, with a focus on the science, people and money that drive the industry.
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints winners and losers 2024: Best and worst biotech trends
Dec 19, 2024 · Endpoints News reviews 2024's biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.
The Endpoints 100: The biotech industry braces for Trump 2.0
Dec 11, 2024 · A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr ...
Federal appeals court says Teva must delist Orange Book inhaler …
Dec 23, 2024 · The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the FDA’s Orange Book.
Big dreams dominate among next-gen biotech players
Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go down fighting for a landmark change.
Commure’s latest acquisition sends follow-up texts to patients
Dec 20, 2024 · General Catalyst-backed Commure acquires Memora Health, a startup that automates patient follow-up texts. Commure continues building healthcare platform.
Major PBM reforms feature in Congress’ year-end spending bill
Dec 17, 2024 · An end-of-year spending bill will include major reforms to the ways pharmacy benefit managers operate, including significant new restrictions on the fees and re ...
Novartis ends Phase 1 radiopharma trial; Solve Therapeutics …
Dec 27, 2024 · Ideaya Biosciences makes an ADC deal with Hengrui Pharma. Amylyx expands GLP-1 work with a new Gubra collaboration.
The Endpoints 100 survey: What are biopharma execs saying …
Dec 11, 2024 · We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at …